2014, Number 2
<< Back Next >>
Rev Invest Clin 2014; 66 (2)
Low-income status is an important risk factor in North East Mexican patients with cystic fibrosis
Sánchez-Domínguez CN, Reyes-López MÁ, Bustamante A, Trevino V, Martínez-Rodríguez HG, Rojas-Martínez A, Barrera-Saldaña HA, Ortíz-López R
Language: English
References: 24
Page: 129-135
PDF size: 240.82 Kb.
ABSTRACT
Background. Factors such as environment, income status,
as well as access to proper healthcare influence the survival
and quality of life of people affected by chronic diseases including
cystic fibrosis (CF). Survival factors in Mexican patients
with CF have not been reported before, even when it has
been estimated that this disease could not be negligible in the
Mexican population.
Objective. To compare the influence of
the mutant allele ΔF508 and environmental factors on the
survival of Mexican CF patients.
Material and methods. We
collected epidemiological data of 40 patients molecularly tested
between 1987 and 2008 in the Clínica de Fibrosis Quística
from the Hospital Universitario of the Universidad Autónoma
de Nuevo León in Northeastern México. Kaplan-Meier plots
and survival statistics were estimated and compared.
Results.
Survival analysis revealed statistical significance for low-income
status (p = 3.13 x 10
-6), cor pulmonale (p = 0.00169),
severe pulmonary disease (p = 0.00136), and BMI
≤15 kg/m
2
(p = 0.00678). Statistical significance was not observed for the
predominant allele ΔF508 considering two (p = 0.992), one
(p = 0.503) or no (p = 0.403) mutant allele.
Conclusions.
Low income status was the most detrimental factor; followed
by cor pulmonale, severe pulmonary disease and BMI
≤15
kg/m
2 for the survival in North East Mexican patients with
CF. Carrying the ΔF508 allele did not influence survival.
REFERENCES
Voter KZ, Ren CL. Diagnosis of cystic fibrosis. Clin Rev Allergy Immunol 2008; 35: 100-06.
O’Sullivan BP, Freedman SD. Cystic fibrosis. Lancet 2009; 373: 1891-904.
Velázquez A, Vela-Amieva M, Naylor EW, Chace DH. Tamiz neonatal ampliado. Rev Mex Pediatr 2000; 67: 206-13.
4 Villalobos-Torres C, Rojas-Martinez A, Villareal-Castellanos E, Cantu JM, Sanchez-Anzaldo FJ, Saiki RK, et al. Analysis of 16 cystic fibrosis mutations in Mexican patients. Am J Med Genet 1997; 69: 380-2.
Chavez-Saldana M, Yokoyama E, Lezana JL, Carnevale A, Macias M, Vigueras RM, et al. CFTR allelic heterogeneity in Mexican patients with cystic fibrosis: implications for molecular screening. Rev Invest Clin 2010; 62: 546-52.
Estivill X, Bancells C, Ramos C. Geographic distribution and regional origin of 272 cystic fibrosis mutations in European populations. The Biomed CF Mutation Analysis Consortium. Hum Mutat 1997; 10: 135-54.
Bobadilla JL, Macek M Jr., Fine JP, Farrell PM. Cystic fibrosis: a worldwide analysis of CFTR mutations—correlation with incidence data and application to screening. Hum Mutat 2002; 19: 575-606.
Orozco L, Velazquez R, Zielenski J, Tsui LC, Chavez M, Lezana JL, et al. Spectrum of CFTR mutations in Mexican cystic fibrosis patients: identification of five novel mutations (W1098C, 846delT, P750L, 4160insGGGG and 297-1G—>A). Hum Genet 2000; 106: 360-5.
Schechter MS. Nongenetic influences on cystic fibrosis outcomes. Curr Opin Pulm Med 2011; 17: 448-54.
Vollmann J, Winau R. Informed consent in human experimentation before the Nuremberg code. BMJ 1996; 313: 1445-9.
López-Romo H. Los niveles socioeconómicos y la distribución del gasto. En: Instituto de Investigaciones Sociales. 2009. Disponible en: www.amai.org/NSE/NivelSocioeconomicoAMAI. pdf
Adkinson N, Bochner B, Busse W, Holgate S, RF L, Simons F. Adherence. In: Middleton’s Allergy: Principles and Practice. 7th Ed. Elsevier Inc.; 2009, p. 1473-83.
Cystic fibrosis: clinical guidelines for diagnosis and treatment. In: Lezana-Fernandez JL (ed.). México, D.F.: Intersistemas editores; 2008.
Manabe T, Higuera Iglesias AL, Vazquez Manriquez ME, Martinez Valadez EL, Ramos LA, Izumi S, et al. Socioeconomic factors influencing hospitalized patients with pneumonia due to influenza A(H1N1)pdm09 in Mexico. PLoS One 2012; 7: e40529.
Schechter MS, Shelton BJ, Margolis PA, Fitzsimmons SC. The association of socioeconomic status with outcomes in cystic fibrosis patients in the United States. Am J Respir Crit Care Med 2001; 163: 1331-7.
O’Connor GT, Quinton HB, Kneeland T, Kahn R, Lever T, Maddock J, et al. Median household income and mortality rate in cystic fibrosis. Pediatrics 2003; 111: e333-e339.
Schechter MS, McColley SA, Silva S, Haselkorn T, Konstan MW, Wagener JS. Association of socioeconomic status with the use of chronic therapies and healthcare utilization in children with cystic fibrosis. J Pediatr 2009; 155: 634-9 e1-4.
Schechter MS, McColley SA, Regelmann W, Millar SJ, Pasta DJ, Wagener JS, et al. Socioeconomic status and the likelihood of antibiotic treatment for signs and symptoms of pulmonary exacerbation in children with cystic fibrosis. J Pediatr 2011; 159: 819-24 e1.
Quittner AL, Schechter MS, Rasouliyan L, Haselkorn T, Pasta DJ, Wagener JS. Impact of socioeconomic status, race, and ethnicity on quality of life in patients with cystic fibrosis in the United States. Chest 2010; 137: 642-50.
Souza dos Santos Simon MI, Drehmer M, de Abreu ESFA, Hoffmann A, Druck Ricachinewsky C, de Fonseca Andrade Procianoy E, et al. Association of nutritional status, plasma, albumin levels and pulmonary function in cystic fibrosis. Nutr Hosp 2011; 26: 1322-7.
Kerem E, Corey M, Kerem BS, Rommens J, Markiewicz D, Levison H, et al. The relation between genotype and phenotype in cystic fibrosis—analysis of the most common mutation (delta F508). N Engl J Med 1990; 323: 1517-22.
Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. N Engl J Med 2005; 352: 1992-2001.
McKone EF, Goss CH, Aitken ML. CFTR genotype as a predictor of prognosis in cystic fibrosis. Chest 2006; 130: 1441-7.
Rohlfs EM, Zhou Z, Heim RA, Nagan N, Rosenblum LS, Flynn K, et al. Cystic fibrosis carrier testing in an ethnically diverse US population. Clin Chem 2011; 57: